Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06446479 · ClinicalTrials.gov registry record · Phase 2
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
A Phase 2 study of Cannabis Use Disorder, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06446479: Recruiting Phase 2 study of Cannabis Use Disorder, sponsored by University of Colorado, Denver.
NCT06446479 is a Phase 2 study of Cannabis Use Disorder that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 28 participants, below the 108-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06446479, a Phase 2 study of Cannabis Use Disorder, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Alcohol and cannabis are often used together such that their effects overlap, but little is known about the neural mechanisms that underlie simultaneous use. High doses of THC have not been well-studied in the laboratory, and it is unclear how high doses of THC may impact alcohol consumption patterns. The proposed study will explore the effects of oral THC (20mg dronabinol) vs. placebo on neural reward, alcohol self-administration and naturalistic co-use patterns.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dronabinol Pill
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT06446479 shows while recruiting
NCT06446479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 108-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06446479 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06446479 about?
NCT06446479 is a clinical study titled "Effects of THC on Alcohol Consumption and Neural Correlates of Reward". Alcohol and cannabis are often used together such that their effects overlap, but little is known about the neural mechanisms that underlie simultaneous use. High doses of THC have not been well-studied in the laboratory, and it is unclear how high doses of THC may impact alcohol consumption pattern...
What is the current status of trial NCT06446479?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-07-01. Estimated completion is 2026-06-30.
What conditions does trial NCT06446479 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT06446479?
The interventions under investigation include: Placebo (DRUG), Dronabinol Pill (DRUG).
Who is sponsoring clinical trial NCT06446479?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06446479 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06446479's enrollment target sits among peer trials
28 29th of 34 higher than 6 of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
A Study of Cannabidiol in Young Adult Cannabis Users
RECRUITING · Phase 2
-
Cannabidiol and Cannabis Concentrate Users
RECRUITING · Phase 2
-
A Teleheath tDCS Approach to Decrease Cannabis Use
COMPLETED · Phase 2
-
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
UH3 Varenicline for Cannabis Use Disorder
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI